219 related articles for article (PubMed ID: 25502225)
1. Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition.
Ulanet DB; Couto K; Jha A; Choe S; Wang A; Woo HK; Steadman M; DeLaBarre B; Gross S; Driggers E; Dorsch M; Hurov JB
PLoS One; 2014; 9(12):e115144. PubMed ID: 25502225
[TBL] [Abstract][Full Text] [Related]
2. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
3. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glutaminase to reverse fibrosis in iatrogenic laryngotracheal stenosis.
Tsai HW; Motz KM; Ding D; Lina I; Murphy MK; Benner D; Feeley M; Hooper J; Hillel AT
Laryngoscope; 2020 Dec; 130(12):E773-E781. PubMed ID: 31904876
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.
Xiang Y; Stine ZE; Xia J; Lu Y; O'Connor RS; Altman BJ; Hsieh AL; Gouw AM; Thomas AG; Gao P; Sun L; Song L; Yan B; Slusher BS; Zhuo J; Ooi LL; Lee CG; Mancuso A; McCallion AS; Le A; Milone MC; Rayport S; Felsher DW; Dang CV
J Clin Invest; 2015 Jun; 125(6):2293-306. PubMed ID: 25915584
[TBL] [Abstract][Full Text] [Related]
7. Recent Development of Small Molecule Glutaminase Inhibitors.
Song M; Kim SH; Im CY; Hwang HJ
Curr Top Med Chem; 2018; 18(6):432-443. PubMed ID: 29793408
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
9. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC.
Lee JS; Kang JH; Lee SH; Hong D; Son J; Hong KM; Song J; Kim SY
Cell Death Dis; 2016 Dec; 7(12):e2511. PubMed ID: 27929535
[TBL] [Abstract][Full Text] [Related]
12. Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines.
Sappington DR; Siegel ER; Hiatt G; Desai A; Penney RB; Jamshidi-Parsian A; Griffin RJ; Boysen G
Biochim Biophys Acta; 2016 Apr; 1860(4):836-43. PubMed ID: 26825773
[TBL] [Abstract][Full Text] [Related]
13. Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
Meijer TWH; Peeters WJM; Dubois LJ; van Gisbergen MW; Biemans R; Venhuizen JH; Span PN; Bussink J
Lung Cancer; 2018 Dec; 126():32-40. PubMed ID: 30527190
[TBL] [Abstract][Full Text] [Related]
14. Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway.
Restall IJ; Cseh O; Richards LM; Pugh TJ; Luchman HA; Weiss S
Cancer Res; 2020 Dec; 80(24):5478-5490. PubMed ID: 33106333
[TBL] [Abstract][Full Text] [Related]
15. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
16. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
Zimmermann SC; Duvall B; Tsukamoto T
J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
[TBL] [Abstract][Full Text] [Related]
19. Glutaminase inhibitors: a patent review.
Wu C; Chen L; Jin S; Li H
Expert Opin Ther Pat; 2018 Nov; 28(11):823-835. PubMed ID: 30273516
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
